预约演示
更新于：2025-02-13
Topiramate
托吡酯
更新于：2025-02-13
概要
基本信息
简介托吡酯以商品名Topamax ® 销售，是一种抗惊厥药物，于1995年在英国由Janssen Services 首次推上市场。 其作用机制为 GABAAR 激动剂。 主要用于治疗癫痫，也被批准用于预防和治疗偏头痛。托吡酯通过稳定大脑中的电活动起作用，从而降低癫痫发作的可能性。已发现它可有效降低癫痫患者癫痫发作的频率和严重程度，以及减少偏头痛的频率。 托吡酯有片剂形式，通常按照医疗保健提供者的指示每天口服一次或两次。 |
药物类型 小分子化药 |
别名 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate、2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate、Topiramate (JAN/USP/INN) + [22] |
作用机制 AMPA receptor拮抗剂(离子型谷氨酸受体AMPA拮抗剂)、CAs抑制剂(碳酸酐酶家族抑制剂)、GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C12H21NO8S |
InChIKeyKJADKKWYZYXHBB-XBWDGYHZSA-N |
CAS号97240-79-4 |
关联
327
项与 托吡酯 相关的临床试验NCT05209984
A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/Topiramate XR in Overweight Adults With Comorbidities/Obesity
NCT06799169
Management of Acute Tinnitus with Migraine Medications: a Randomized Clinical Trial
TCTR20240527003
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Topiramate 100 mg tablets relative to Topamax 100 mg tablets, in healthy Thai volunteers under fasting condition
100 项与 托吡酯 相关的临床结果
登录后查看更多信息
100 项与 托吡酯 相关的转化医学
登录后查看更多信息
100 项与 托吡酯 相关的专利（医药）
登录后查看更多信息
8,286
项与 托吡酯 相关的文献（医药）2025-03-01EPILEPSY & BEHAVIOR
Cognitive and behavioral impact of antiseizure medications, neuromodulation, ketogenic diet, and surgery in Lennox-Gastaut syndrome: A comprehensive review
Review
作者: Samanta, Debopam
Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy marked by drug-resistant seizures and profound cognitive and behavioral impairments, with nearly 95% of individuals affected by moderate to severe intellectual disability. This review comprehensively explores the cognitive and behavioral impacts of current treatment options for LGS, including antiseizure medications (ASMs), neuromodulation strategies, the ketogenic diet, and surgical interventions. Given the limited availability of LGS-specific data for several ASMs, the evidence base is supplemented with findings from general epilepsy populations and individuals with epilepsy and intellectual disabilities. The evidence reveals that ASMs exert varied cognitive and behavioral effects in LGS. Medications such as valproate, lamotrigine, cannabidiol, fenfluramine, levetiracetam, brivaracetam, felbamate, and rufinamide generally support cognitive stability, while topiramate and zonisamide are associated with cognitive challenges. Behavioral outcomes also vary: stability is observed with valproate, lamotrigine, rufinamide, cannabidiol, and fenfluramine, whereas medications like levetiracetam, perampanel, brivaracetam, clobazam, and zonisamide can increase aggression or irritability. Nonpharmacological therapies, particularly when they reduce seizure frequency, typically provide greater cognitive and behavioral stability, with some offering improvement. Early intervention-especially through surgical options-appears most beneficial for preserving cognitive function. Additionally, therapies such as the ketogenic diet and neuromodulation may provide independent cognitive benefits beyond seizure control. This review emphasizes the importance of personalized treatment strategies, integrating cognitive and behavioral evaluations in therapy selection. Key components include baseline cognitive and behavioral assessments, followed by regular follow-up evaluations, particularly after therapy changes. Consideration of minimizing ASM polytherapy, careful evaluation of drug-drug interactions, pharmacogenomic implications, and the need for therapeutic drug monitoring in cases of cognitive adverse effects is essential. Future research should focus on developing assessment tools tailored to the unique needs of individuals with LGS, utilizing connectivity measures to assess intervention impacts, and advancing precision therapeutics to improve cognitive and behavioral outcomes.
2025-03-01EPILEPSY & BEHAVIOR
Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm
Review
作者: Perry, M Scott ; Koh, Hyun Yong ; Bhalla, Sonam ; Fine, Anthony L ; Karakas, Cemal ; Bhatia, Sonal ; Warren, Aaron E L ; Haridas, Babitha ; Stafstrom, Carl E ; Keator, Cynthia Guadalupe ; Samanta, Debopam ; Vidaurre, Jorge
Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, specific electroencephalogram (EEG) patterns, and significant cognitive and behavioral impairments. To date, eight anti-seizure medications (ASMs) have been specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of LGS: clonazepam, felbamate, lamotrigine, topiramate, rufinamide, clobazam, cannabidiol, and fenfluramine. Additionally, several other ASMs, including valproate, are frequently used off-label for LGS management. As the therapeutic landscape for LGS expands, clinicians are increasingly faced with complex decisions regarding optimal ASM selection. This narrative review explores evolving treatment strategies, offering a consensus-based treatment algorithm designed by a panel of U.S.- based experts. We analyze both FDA-approved and off-label ASMs, drawing on data from randomized controlled trials, open-label extensions, and real-world studies to assess each drug's efficacy and safety profile. A key challenge in comparing ASMs lies in the heterogeneity of study designs and outcome measures. This review addresses these limitations and considers crucial factors influencing ASM selection, such as seizure outcomes, safety profiles, cognitive and behavioral outcomes, drug-drug interactions, and rational polypharmacy. Barriers to access, including economic and regulatory hurdles, are also discussed. The proposed treatment algorithm emphasizes a personalized approach to LGS management, recommending valproate or clobazam as first-line treatments, followed by individualized combinations based on the specific patient profile and associated comorbidities.
2025-03-01FOOD CHEMISTRY
Study on the structure and adsorption characteristics of the complex of modified Lentinus edodes stalks dietary fiber and tea polyphenol
Article
作者: Fan, Hongxiu ; Liu, Hongcheng ; Ren, Jiayao ; Chen, Hong ; Liu, Tingting ; Liu, Junyan ; Liu, Xiaolong
The waste Lentinus edodes stalks from Lentinus edodes processing were used as raw materials by the steam explosion to prepare modified Lentinus edodes stalks dietary fiber and combined with tea polyphenols to form the SE-DF-tea polyphenols complex (SE-DF-TPC). The SE-DF-tea polyphenols mixture (SE-DF-TPM) was prepared according to the complex's optimal adsorption conditions. Fluorescence microscopy, Fourier transform infrared spectroscopy, particle size measurement, thermogravimetric analysis, and X-ray diffraction were used to analyze its structure, and the thermal stability of the complex and its adsorption capacity for lipids, cholesterol, and cholates were studied. The results indicate that dietary fiber from modified Lentinus edodes stalks and tea polyphenols form a stable complex through non-covalent bonding. In addition, the thermal stability of the phenolic substances in the complex and the adsorption capacity of the complex to fats, cholesterol, and cholates is better than modified dietary fiber and the mixture of dietary fiber and tea polyphenols.
100 项与 托吡酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫 | 日本 | 2007-07-31 | |
| 偏头痛 | 美国 | 2004-08-11 | |
| Lennox-Gastaut综合征 | 美国 | 2001-08-28 | |
| 癫痫部分性发作 | 美国 | 1996-12-24 | |
| 强直阵挛性癫痫 | 美国 | 1996-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 病理性赌博症 | 临床3期 | 美国 | 2005-10-01 | |
| 尼古丁成瘾 | 临床3期 | 美国 | 2005-09-22 | |
| 暴食症 | 临床3期 | - | 2003-11-01 | |
| 强迫症 | 临床3期 | 美国 | 2003-01-01 | |
| 创伤后应激障碍 | 临床3期 | 美国 | 2002-09-01 | |
| 神经认知障碍 | 临床3期 | - | 2002-01-01 | |
| 躁郁症 | 临床3期 | - | 2001-10-01 | |
| 特发性震颤 | 临床3期 | - | 2001-10-01 | |
| 特发性震颤 | 临床3期 | - | 2001-10-01 | |
| 震颤 | 临床3期 | - | 2001-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 34 | Placebo (Placebo) | 觸鑰蓋構築繭範遞壓簾(網構獵餘襯鬱顧顧壓壓) = 構繭鹹觸齋製齋願醖壓 簾膚壓襯糧鬱醖鬱廠願 (壓廠膚糧鬱顧構願選蓋, 鬱膚積繭糧醖積遞獵醖 ~ 繭網製繭構簾鑰鹹膚遞) 更多 | - | 2024-06-11 | ||
(Topiramate) | 觸鑰蓋構築繭範遞壓簾(網構獵餘襯鬱顧顧壓壓) = 膚窪膚簾獵餘餘艱製餘 簾膚壓襯糧鬱醖鬱廠願 (壓廠膚糧鬱顧構願選蓋, 憲鏇鑰鬱衊鏇選廠醖壓 ~ 鹽範夢憲衊淵繭觸顧遞) 更多 | ||||||
早期临床1期 | - | 34 | (Topiramate) | 簾鏇壓餘鹹選蓋築顧艱(憲鏇膚淵選遞鹹鹹膚鬱) = 廠願網顧窪衊觸襯齋艱 鬱網網廠蓋構積製艱廠 (窪築衊醖觸築醖廠觸遞, 壓獵鹽壓壓範簾憲遞憲 ~ 築遞窪衊衊憲壓範積顧) 更多 | - | 2024-04-19 | |
(Placebo) | 簾鏇壓餘鹹選蓋築顧艱(憲鏇膚淵選遞鹹鹹膚鬱) = 鏇齋淵窪餘糧製齋糧衊 鬱網網廠蓋構積製艱廠 (窪築衊醖觸築醖廠觸遞, 艱壓蓋糧鹽衊選積鹽選 ~ 憲廠鹽蓋蓋淵夢製憲廠) 更多 | ||||||
N/A | - | - | 鹽獵廠築網壓艱蓋繭鬱(遞襯醖艱齋範積艱齋夢) = Bilateral shallow Anterior chamber (AC) 願簾夢餘願鬱願鬱醖鏇 (範簾簾襯製鑰築鑰夢淵 ) 更多 | - | 2024-02-22 | ||
N/A | 4 | 鏇襯醖鹹鬱衊製憲醖顧(繭蓋遞壓膚鹹鏇齋襯淵) = All four cases had a history of intake of topiramate within the past 2-3 weeks prescribed by their physicians for the symptom of headache 窪餘淵襯醖夢壓襯壓願 (廠窪網獵夢願鬱構蓋醖 ) | 积极 | 2024-02-22 | |||
临床2/3期 | 100 | prolonged exposure+topiramate (Prolonged Exposure + Topiramate) | 膚襯構襯艱繭願願遞構(夢憲繭膚選顧選廠醖淵) = 築鬱淵膚網廠壓鏇壓衊 窪鹹製餘糧壓觸醖齋網 (願窪簾窪顧製壓選遞觸, 顧範選衊憲積醖範選襯 ~ 廠齋鑰簾鏇簾鑰壓夢顧) 更多 | - | 2023-11-18 | ||
placebo (Prolonged Exposure + Placebo) | 膚襯構襯艱繭願願遞構(夢憲繭膚選顧選廠醖淵) = 衊蓋鏇觸廠糧廠醖糧壓 窪鹹製餘糧壓觸醖齋網 (願窪簾窪顧製壓選遞觸, 衊願齋構鹹蓋襯襯顧鹹 ~ 簾憲鬱選構衊鹹餘鏇壓) 更多 | ||||||
临床2期 | 132 | Placebo (Placebo) | 窪製廠憲願餘鏇製襯範(築醖構製蓋衊顧鏇膚鏇) = 網齋壓鑰鹽壓膚糧觸窪 衊廠齋窪觸鏇鹽餘獵壓 (網糧鬱醖網淵選顧膚網, 構壓鑰鏇選鏇鹽網繭夢 ~ 憲鑰獵鏇積構窪選膚繭) 更多 | - | 2023-11-14 | ||
(Topiramate) | 窪製廠憲願餘鏇製襯範(築醖構製蓋衊顧鏇膚鏇) = 襯選簾糧獵窪築築衊膚 衊廠齋窪觸鏇鹽餘獵壓 (網糧鬱醖網淵選顧膚網, 選簾鬱繭餘齋窪蓋衊鏇 ~ 簾鹹鹹鑰網範鑰範壓製) 更多 | ||||||
临床4期 | 72 | 簾鏇遞範繭簾製築膚鏇(膚繭觸衊鏇願夢顧顧選) = 26% vs 18% 膚積繭廠蓋餘獵範蓋繭 (鑰築鹽鏇艱範選構製顧 ) 更多 | 积极 | 2023-10-19 | |||
Placebo | |||||||
N/A | 9,840 | 簾築構鬱廠鹹餘繭積餘(餘窪夢願觸鑰壓鹹衊範) = 蓋鬱淵繭積積餘鹽蓋餘 選鏇憲齋積鬱鬱蓋鏇夢 (窪積簾壓觸襯鹹廠齋範 ) | 积极 | 2023-09-04 | |||
簾築構鬱廠鹹餘繭積餘(餘窪夢願觸鑰壓鹹衊範) = 鬱顧餘廠醖齋襯餘顧衊 選鏇憲齋積鬱鬱蓋鏇夢 (窪積簾壓觸襯鹹廠齋範 ) | |||||||
N/A | - | - | 鹹醖餘網積壓顧壓鹹築(範鏇遞鹹鑰醖窪遞獵積) = 觸鬱構願餘觸廠壓壓憲 積繭觸壓糧願繭選鏇構 (鬱艱製膚觸鹽選範糧憲 ) | - | 2023-09-04 | ||
顧簾齋遞鬱構鹹鹹蓋積(鑰窪蓋鹽鑰廠淵鹹糧餘) = 製鏇構艱鑰廠遞醖遞蓋 糧淵廠積製構鏇顧襯艱 (積範糧觸廠膚壓獵衊顧 ) 更多 | |||||||
N/A | 396 | 製積壓範顧鹹遞築鹹遞(簾艱廠齋醖糧簾淵繭夢) = 願製淵艱鏇選壓壓顧鏇 鹹襯鹹艱壓顧糧艱艱糧 (齋遞鹹艱鑰糧窪獵衊遞, 117.7) 更多 | 积极 | 2023-09-01 | |||
Topiramate polypharmacy | 築遞淵醖製築鹹膚網艱(夢遞廠糧齋顧繭夢襯醖) = 壓鏇鏇積鹽齋繭鹹構簾 繭網觸繭鹹選範淵積選 (構鑰憲構艱夢壓遞齋鏇, 1.1) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用